Lockstat Gold Capsule is a combination pharmaceutical formulation containing Aspirin (75 mg), Rosuvastatin (10 mg), and Clopidogrel (75 mg), designed for the management of cardiovascular conditions requiring antiplatelet and lipid-lowering therapy. Aspirin, a well-established antiplatelet agent, irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 production and thereby preventing platelet aggregation. Clopidogrel, a P2Y12 receptor antagonist, further inhibits platelet activation and aggregation, providing a synergistic effect with Aspirin in reducing the risk of thrombotic events such as myocardial infarction and stroke. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) levels, contributing to the prevention of atherosclerosis progression. Lockstat Gold Capsule is indicated for patients with established cardiovascular disease or those at high risk, requiring combined antiplatelet therapy alongside lipid management to reduce morbidity and mortality associated with coronary artery disease and cerebrovascular events. The combination therapy optimizes patient compliance by reducing pill burden. Use of Lockstat Gold Capsule should be under strict medical supervision, considering potential contraindications and monitoring for adverse effects such as bleeding risk, hepatic dysfunction, and myopathy. Regular follow-up and laboratory assessments are recommended to ensure therapeutic efficacy and safety.